Kidney Graft Function Under the Immunosuppression Strategies

NCT01817322 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

140

Enrollment

OTHER

Sponsor class

Conditions

Chronic Renal Disease

Interventions

DRUG: Standard Dose of Myfortic and Reduced Dose of Myfortic
DRUG: Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group
DRUG: Basiliximab injected both control group and experimental group

Sponsor

Samsung Medical Center